Pramipexole‐induced somnolence and episodes of daytime sleep
Identifieur interne : 004988 ( Main/Exploration ); précédent : 004987; suivant : 004989Pramipexole‐induced somnolence and episodes of daytime sleep
Auteurs : Robert A. Hauser [États-Unis] ; Lisa Gauger [États-Unis] ; W. Mcdowell Anderson [États-Unis] ; Theresa A. Zesiewicz [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2000-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Agonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Automobile Driving, Benzothiazoles, D2 Dopamine receptor, Dose-Response Relationship, Drug, Double-Blind Method, Driving, Female, Human, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Narcolepsy (chemically induced), Narcolepsy (diagnosis), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Polysomnography, Pramipexole, Retrospective Studies, Sleep, Somnolence, Thiazoles (adverse effects), Thiazoles (therapeutic use), Toxicity, Vehicle driving.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa, Thiazoles.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa, Thiazoles.
- chemically induced : Narcolepsy.
- diagnosis : Narcolepsy.
- drug therapy : Parkinson Disease.
- Aged, Automobile Driving, Benzothiazoles, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Polysomnography, Retrospective Studies.
Abstract
Pramipexole is a non‐ergot dopamine agonist used to treat Parkinson's disease (PD). Because of concern regarding driving safety, we evaluated the incidence and nature of somnolence experienced by patients receiving pramipexole in clinical trials at our center. A retrospective chart review was performed and structured interviews were conducted with patients who had reported moderate or severe somnolence. In addition, two patients underwent polysomnography (PSG) and multiple sleep latency tests (MSLT) while on and 2 weeks after discontinuation of pramipexole. Forty patients with PD participating in pramipexole clinical trials were identified. In the double‐blind phases of the studies, 22 patients were randomized to pramipexole and 18 were randomized to placebo. Six patients assigned to pramipexole reported somnolence as an adverse event (1 moderate, 5 mild) compared with two patients assigned to placebo (1 severe, 1 moderate; p = 0.19, one‐tailed Fisher's exact test). Thirty‐seven patients participated in open‐label extension studies. Twenty‐one (57%) reported somnolence as an adverse event. Eleven (30%) patients reported moderate somnolence and three (8%) patients reported severe somnolence. For patients with moderate or severe somnolence, the onset of worst‐reported somnolence occurred at a mean (± standard error) pramipexole dose of 4.0 ± 0.4 mg (range, 0.75–4.5 mg) per day. Patients had been taking pramipexole for a total of 10.0 ± 1.5 months (range, .03–22 mos) and at their maximal dose for 6.7 ± 1.5 months (range, .03–20 mos). During structured interviews with 12 of the 14 patients reporting moderate or severe somnolence, seven reported falling asleep while driving and two reported minor motor vehicle accidents caused by falling asleep. Most patients reported relatively continuous drowsiness that led to falling asleep without acute warning during periods of inactivity. Three patients reported discreet waves of irresistible sleepiness heralded by prodromal symptoms occurring against a background of normal wakefulness. MSLT in two of these patients revealed decreased latency to sleep without early onset of rapid eye movements. Sleep latency normalized after withdrawal of pramipexole. Intensive patient education is necessary to prevent motor vehicle accidents in patients taking pramipexole. We recommend that patients who are experiencing generalized drowsiness and falling asleep during periods of inactivity be instructed not to drive because these patients do fall asleep without acute warning. Somnolence usually resolves with pramipexole dose reduction or discontinuation. Patients should also be alerted to pull over and stop driving immediately if they feel a wave of sleepiness coming on. Patient education and compliance are critical to maximize safety.
Url:
DOI: 10.1002/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E98
- to stream Istex, to step Curation: 000E98
- to stream Istex, to step Checkpoint: 003188
- to stream Main, to step Merge: 007285
- to stream PascalFrancis, to step Corpus: 002B92
- to stream PascalFrancis, to step Curation: 000129
- to stream PascalFrancis, to step Checkpoint: 002B36
- to stream Main, to step Merge: 007528
- to stream PubMed, to step Corpus: 003F50
- to stream PubMed, to step Curation: 003F50
- to stream PubMed, to step Checkpoint: 003E99
- to stream Ncbi, to step Merge: 000301
- to stream Ncbi, to step Curation: 000301
- to stream Ncbi, to step Checkpoint: 000301
- to stream Main, to step Merge: 007042
- to stream Main, to step Curation: 004988
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pramipexole‐induced somnolence and episodes of daytime sleep</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Gauger, Lisa" sort="Gauger, Lisa" uniqKey="Gauger L" first="Lisa" last="Gauger">Lisa Gauger</name>
</author>
<author><name sortKey="Anderson, W Mcdowell" sort="Anderson, W Mcdowell" uniqKey="Anderson W" first="W. Mcdowell" last="Anderson">W. Mcdowell Anderson</name>
</author>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:74BB0DBF27DADA511E43DDBD2355036505DFF481</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N</idno>
<idno type="url">https://api.istex.fr/document/74BB0DBF27DADA511E43DDBD2355036505DFF481/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E98</idno>
<idno type="wicri:Area/Istex/Curation">000E98</idno>
<idno type="wicri:Area/Istex/Checkpoint">003188</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:pramipexole:induced:somnolence</idno>
<idno type="wicri:Area/Main/Merge">007285</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0394545</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B92</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000129</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B36</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:pramipexole:induced:somnolence</idno>
<idno type="wicri:Area/Main/Merge">007528</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10928575</idno>
<idno type="wicri:Area/PubMed/Corpus">003F50</idno>
<idno type="wicri:Area/PubMed/Curation">003F50</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E99</idno>
<idno type="wicri:Area/Ncbi/Merge">000301</idno>
<idno type="wicri:Area/Ncbi/Curation">000301</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000301</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Hauser R:pramipexole:induced:somnolence</idno>
<idno type="wicri:Area/Main/Merge">007042</idno>
<idno type="wicri:Area/Main/Curation">004988</idno>
<idno type="wicri:Area/Main/Exploration">004988</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pramipexole‐induced somnolence and episodes of daytime sleep</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa General Hospital, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Gauger, Lisa" sort="Gauger, Lisa" uniqKey="Gauger L" first="Lisa" last="Gauger">Lisa Gauger</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Anderson, W Mcdowell" sort="Anderson, W Mcdowell" uniqKey="Anderson W" first="W. Mcdowell" last="Anderson">W. Mcdowell Anderson</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Medicine, University of South Florida, Tampa General Hospital, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of South Florida, Tampa General Hospital, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-07">2000-07</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="658">658</biblScope>
<biblScope unit="page" to="663">663</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">74BB0DBF27DADA511E43DDBD2355036505DFF481</idno>
<idno type="DOI">10.1002/1531-8257(200007)15:4<658::AID-MDS1009>3.0.CO;2-N</idno>
<idno type="ArticleID">MDS1009</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Agonist</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Automobile Driving</term>
<term>Benzothiazoles</term>
<term>D2 Dopamine receptor</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Driving</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Narcolepsy (chemically induced)</term>
<term>Narcolepsy (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Polysomnography</term>
<term>Pramipexole</term>
<term>Retrospective Studies</term>
<term>Sleep</term>
<term>Somnolence</term>
<term>Thiazoles (adverse effects)</term>
<term>Thiazoles (therapeutic use)</term>
<term>Toxicity</term>
<term>Vehicle driving</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Thiazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Narcolepsy</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Narcolepsy</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Automobile Driving</term>
<term>Benzothiazoles</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Polysomnography</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Agoniste</term>
<term>Conduite véhicule</term>
<term>Homme</term>
<term>Parkinson maladie</term>
<term>Pramipexole</term>
<term>Récepteur dopaminergique D2</term>
<term>Somnolence</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Pramipexole is a non‐ergot dopamine agonist used to treat Parkinson's disease (PD). Because of concern regarding driving safety, we evaluated the incidence and nature of somnolence experienced by patients receiving pramipexole in clinical trials at our center. A retrospective chart review was performed and structured interviews were conducted with patients who had reported moderate or severe somnolence. In addition, two patients underwent polysomnography (PSG) and multiple sleep latency tests (MSLT) while on and 2 weeks after discontinuation of pramipexole. Forty patients with PD participating in pramipexole clinical trials were identified. In the double‐blind phases of the studies, 22 patients were randomized to pramipexole and 18 were randomized to placebo. Six patients assigned to pramipexole reported somnolence as an adverse event (1 moderate, 5 mild) compared with two patients assigned to placebo (1 severe, 1 moderate; p = 0.19, one‐tailed Fisher's exact test). Thirty‐seven patients participated in open‐label extension studies. Twenty‐one (57%) reported somnolence as an adverse event. Eleven (30%) patients reported moderate somnolence and three (8%) patients reported severe somnolence. For patients with moderate or severe somnolence, the onset of worst‐reported somnolence occurred at a mean (± standard error) pramipexole dose of 4.0 ± 0.4 mg (range, 0.75–4.5 mg) per day. Patients had been taking pramipexole for a total of 10.0 ± 1.5 months (range, .03–22 mos) and at their maximal dose for 6.7 ± 1.5 months (range, .03–20 mos). During structured interviews with 12 of the 14 patients reporting moderate or severe somnolence, seven reported falling asleep while driving and two reported minor motor vehicle accidents caused by falling asleep. Most patients reported relatively continuous drowsiness that led to falling asleep without acute warning during periods of inactivity. Three patients reported discreet waves of irresistible sleepiness heralded by prodromal symptoms occurring against a background of normal wakefulness. MSLT in two of these patients revealed decreased latency to sleep without early onset of rapid eye movements. Sleep latency normalized after withdrawal of pramipexole. Intensive patient education is necessary to prevent motor vehicle accidents in patients taking pramipexole. We recommend that patients who are experiencing generalized drowsiness and falling asleep during periods of inactivity be instructed not to drive because these patients do fall asleep without acute warning. Somnolence usually resolves with pramipexole dose reduction or discontinuation. Patients should also be alerted to pull over and stop driving immediately if they feel a wave of sleepiness coming on. Patient education and compliance are critical to maximize safety.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Anderson, W Mcdowell" sort="Anderson, W Mcdowell" uniqKey="Anderson W" first="W. Mcdowell" last="Anderson">W. Mcdowell Anderson</name>
<name sortKey="Gauger, Lisa" sort="Gauger, Lisa" uniqKey="Gauger L" first="Lisa" last="Gauger">Lisa Gauger</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004988 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004988 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:74BB0DBF27DADA511E43DDBD2355036505DFF481 |texte= Pramipexole‐induced somnolence and episodes of daytime sleep }}
This area was generated with Dilib version V0.6.23. |